CRDF Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	586 155
Average Volume	1.86M
Market Cap	178.26M
EPS	$0 ( 2024-02-29 )
Next earnings date	( $-0.250 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.29
ATR14	$0.00800 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-07	Levine James E.	Buy	205 008	Stock Options
2024-03-07	Kabbinavar Fairooz	Buy	205 008	Stock Options
2024-03-07	Smeal Tod	Buy	205 008	Stock Options
2024-03-07	Erlander Mark	Buy	510 000	Stock Options
2023-12-19	Pace Gary W	Buy	30 000	Common Stock

INSIDER POWER
81.91
Last 96 transactions
Buy: 6 518 913 \| Sell: 700 088

Volume Correlation

Long: -0.17 (neutral)

Short: -0.87 (strong negative)

Signal:(34.524) Neutral

Cardiff Oncology Inc Correlation

10 Most Positive Correlations
CCOI	0.854
GGAL	0.854
EUFN	0.854
FGM	0.847
TRVG	0.846
FEP	0.842
CID	0.838
KDNY	0.836
SMMT	0.836
NWLI	0.835

10 Most Negative Correlations
MGTA	-0.807
MOSY	-0.807
PCRX	-0.807
SGLB	-0.805
MBCN	-0.803

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cardiff Oncology Inc Correlation - Currency/Commodity

0.38
( neutral )

0.33
( neutral )

0.00
( neutral )

-0.33
( neutral )

0.07
( neutral )

Cardiff Oncology Inc Financials

Annual	2023
Revenue:	$488 000
Gross Profit:	$90 000.00 (18.44 %)
EPS:	$-0.930

Q4	2023
Revenue:	$156 000
Gross Profit:	$53 000.00 (33.97 %)
EPS:	$-0.210

Q3	2023
Revenue:	$141 000
Gross Profit:	$34 000.00 (24.11 %)
EPS:	$-0.220

Q2	2023
Revenue:	$108 000
Gross Profit:	$10 000.00 (9.26 %)
EPS:	$-0.250

Financial Reports:

No articles found.

Cardiff Oncology Inc

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.